Background We studied if Micarna-206 (MIR-206) is abnormally expressed in patients with coronary artery disease (CAD). The potential mechanism by which MIR-206 can regulate the progress of the CAD has also been studied. Material and methods A total of 78 CAD patients in the business group and 65 topics of the control group were recorded in this study so that the correlation between MIR-206 and the CAD can be precisely determined. Cholesterol Total cholesterol serum, high-density lipoprotein cholesterol, low density and triglyceride lipoprotein cholesterol have been detected using a biochemistry analyzer.
The expression levels of expression of endothelial growth MIR-206 and vascular growth have been tested using the reaction of the polymerase chain of reverse transcription or western blot. The associations between the expression mir-206 and various clinicopathological characteristics of CAD patients were also analyzed. CAD cells were transfected with MIR-206 MIMIC (MIR-206), its negative control (MIR-NC), a MIR-206 inhibitor (Anti-Mir-206) and its negative control (Anti-Mir-NC), respectively. The flow cytometry was performed to explore the mir-206 function in the apoptosis of the CAD cell after transfection.
In addition, Transwell Test was conducted to study the migratory capacity of endothelial progenitor cells in CAD patients. Results The expression mir-206 has been enriched in patient CPCs and plasma patients with CAD. No significant correlation has been found between the decrease in the expression MIR-206 and different clinicalopathological characteristics. In addition, MIR-206 has significantly removed the viability and invasion of CPS in CAD patients, and has favored apoptosis of their CBC. In addition, we found that Mir-206 is capable of inhibiting VEGF’s expression. Conclusions As suggested by our study, MIR-206 can be a new Benin CAD biomarker because it can regulate the expression of VEGF.
Comparison of serum sodium levels measured by the blood gas analyzer and self-analyzer biochemistry in patients with hyponatremia, euunaral and hypernatremia.
CONTEXT
The electrolyte measurements of the blood gas analyzer (BGA) are frequently used in emergency departments (EDS) pending biochemistry laboratory Autoanalyzer (BLA) results. There is a lack of data in the literature in terms of agreement of these 2 sodium measurement methods. We aim to exhaustively evaluate the agreement in hyponatremia, eunaRemémies and hypernatremia groups.
Methods
In retrospect, adult topics that have presented to ED of a tertiary care hospital and have had simultaneous results BGA and BLA were included in the study. Blood pairs have been grouped in hyponatremia, EuunaRemémies and Hypernatremies according to the results of the bla. The sodium measurement agreement between the methods was evaluated by Parcels of Bland-Altman and a Bablok regression analysis.
RESULTS
A total of 2557 blood pairs (1326 males [51.8%]) were included. The median age of patients was 66 (18-103). The number of patients with hyponatremia, euunarate and hypernatremia was 487 (19%), 1943 (76%) and 127 (5%), respectively. Minimum and maximum sodium rate measured by biochemistry analyzer were 106 and 171 mmol / L. The Pearson linear correlation coefficient between BGA and BLA for sodium measurements was 0.574, 0.358 and 0.562 in hyponatremia groups, EuunaRemémies and Hypernatremia, respectively. The average absolute difference for the 3 groups was greater than 4 mmol / l. Laboratory of Biochemistry Autoanalyzer has tended to measure serum sodium higher than the BGA in all sodium groups. The analysis of regression by the passing and Bablok showed significant differences between the 2 methods of all sodium groups.
Conclusions
This is the first overall assessment of the agreement between BGA and Bla in separate sodium groups. Significant differences must be taken into account when these patients are managed in ED.
MiR-206 Suppresses the Progression of Coronary Artery Disease by Modulating Vascular Endothelial Growth Factor (VEGF) Expression.
Blood gas test and related measures: national recommendations on behalf of the Croatia Society of Medical Biochemistry and Laboratory Medicine.
Blood gas analysis (BGA) is exposed to the risk of errors caused by inappropriate sampling, transport and storage conditions. The Institute of Clinical Standards and Laboratory (CLSI) has generated documents with recommendations to avoid potential errors caused by poor manipulation. Two main documents related to the BGA issued by the CLSIs are GP43-A4 procedures (formerly H11-A4) for the collection of arterial blood specimens; standard approved – fourth edition and analysis of blood gas and pH C46-A2 and related measures; Approved Directive – Second Edition.
Practices related to the treatment of blood gas samples are not standardized in the Republic of Croatia. Each institution has its own control protocol, collecting and analyzing blood gases. Although many laboratories use the state of the analyzers of the art, many preanalytic procedures remain unchanged. The objective of the Croatian Society for Medical Biochemistry and Laboratory Medicine (CSMBLM) is to standardize BGA procedures based on CLSI recommendations.
The Blood Gas Test Working Group In the framework of the CSMBLM Scientific Professional Development Committee has prepared a set of protocols recommended for sampling, transporting, storing and transforming blood gas samples based on Relevant CLSI Documents, Relevant Literature Research and the results of the Croatian Survey Study on Acidic Basic Testing. The recommendations are intended for laboratory professionals and all health workers involved in the treatment of blood gas. The Turtle Sulcata or the African Turtle (Centryelys Sulcata) is a great kind of turtle that is commonly preserved in zoological collections and as a pet.
Description: Pyrene is a polyaromatic hydrocarbon with strong short-wavelength fluorescence. Unlike other fluorescent dyes, polyaromatic hydrocarbons are fluorescent probes with strong sensitivity to microenvironment. Thus, its fluorescence is different in polar, and nonpolar environments.
Description: Pyrene is a polyaromatic hydrocarbon with strong short-wavelength fluorescence. Unlike other fluorescent dyes, polyaromatic hydrocarbons are fluorescent probes with strong sensitivity to microenvironment. Thus, its fluorescence is different in polar, and nonpolar environments.
Description: This pyrene azide is a derivative of pyrenebutyric acid. Contains triethylene glycol linker to facilitate dissolution during labeling reaction.
Description: This pyrene azide is a derivative of pyrenebutyric acid. Contains triethylene glycol linker to facilitate dissolution during labeling reaction.
Description: Pyrene is polycyclic aromatic hydrocarbon which is well-known for its ability to intercalate into DNA. Pyrene features intense blue fluorescence. Its parameters depend strongly on fluorophore microenvironment.
Description: A competitive ELISA kit for quantitative measurement of Human BPDE (Benzo Pyrene Dihydrodiol Epoxide) in samples from Serum, Plasma, Cell supernatant
Description: A competitive ELISA for quantitative measurement of Rat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Canine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Porcine Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Goat Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Human Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Mouse Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Rabbit Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Monkey Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
PAH Std 2.37.8-Di-(peri-naphthylene)-pyrene 200ug/mL in Toluene
Description: A competitive ELISA for quantitative measurement of Guinea pig Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Description: A competitive ELISA for quantitative measurement of Guinea pig Benzo Pyrene Dihydrodiol Epoxide in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.
Human Benzo Pyrene Dihydrodiol Epoxide(BPDE)ELISA Kit
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is unconjugated.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to APC .
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Biotin.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Dylight 350.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Dylight 405.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Dylight 488.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Dylight 594.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Dylight 633.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to FITC.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to HRP.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to PE/ATTO 594.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to PerCP.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to RPE .
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is conjugated to Streptavidin.
Description: A polyclonal antibody for beta Actin from Human. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein range of human beta Actin. The Antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100). This beta Actin antibody is unconjugated.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is unconjugated.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 390.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 488.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 565.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 594.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 633.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 655.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 680.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to ATTO 700.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to Alkaline Phosphatase.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to APC .
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to APC/Cy7.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to Biotin.
Description: A polyclonal antibody for beta Actin (pTyr53) from Human. The antibody is produced in rabbit after immunization with Human A phospho-specific peptide corresponding to residues surrounding Tyr53 of human beta Actin (AA50-56). The Antibody is tested and validated for WB, AM assays with the following recommended dilutions: WB (1:250). This beta Actin (pTyr53) antibody is conjugated to Dylight 350.
×
The objectives of this study were to establish reference intervals for selected biochemical analytes in clinically healthy sulcatata turtles and evaluate the impact of the blood and gender sampling site. The blood samples were collected from 60 turtles of the dorsal cocccygall vein (tail) or subcarapacial venous plexus based on their body size. The volume of the packed cell and the refrigerating total solids (TS) were determined.
Madeline
